09/14/2017 - Microbiotix and the AMR Centre Announce Co-Development Agreement Targeting Drug Resistant P. aeruginosa in Critically Ill Pneumonia Patients.

03/30/2017 - CARB-X injects up to $48 million to accelerate first Powered by CARB-X portfolio of drug discovery and development projects to tackle antibiotic resistance.

05/01/2012 - Microbiotix received a NIH/NIAID Phase II grant to discover novel methylenecyclopropane derivatives with potent activity against alpha-, beta- and gamma-herpesviruses.

04/03/2012 – Microbiotix received a NIH/NIAID R01 grant to identify and validate targets in the type III secretion (T3SS) pathway that are potentially useful for future drug discovery.

08/01/2011 – Microbiotix received a NIH/NIAID SBIR Phase II grant to optimize the phenoxyacetamide series of T3SS inhibitors and establish potency and selectivity in animal models of P. aeruginosa infection.

2/11/2009 Microbiotix receives an NIAID SBIR Phase I grant to develop a novel series of purine nucleoside analogs for therapeutic efficacy against emerging infectious disease agents HHV-6 and HHV-8.

9/1/2008 Microbiotix receives an SBIR Phase II Renewal grant to develop an expanded IV preclinical biological profile of a second generation methylenecyclopropane for treatment of CMV infections and to file an Investigational New Drug (IND) application.

8/15/2008 Microbiotix receives an NIAID SBIR Phase I grant to discover and characterize new agents inhibiting the entry of influenza virus into host cells.